Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

fresenius kabi usa, llc - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 10 mg in 1 ml - famotidine injection, supplied as a concentrated solution for intravenous injection, is intended for intravenous use only. famotidine injection is indicated in some hospitalized patients with pathological hypersecretory conditions or intractable ulcers, or as an alternative to the oral dosage forms for short term use in patients who are unable to take oral medication for the following conditions: - short term treatment of active duodenal ulcer . most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. - short term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

baxter healthcare corporation - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg in 50 ml - famotidine injection is supplied as a premixed solution in galaxy plastic containers (pl 2501 plastic) and is intended for intravenous use only. famotidine injection is indicated in some hospitalized patients with pathological hypersecretory conditions or intractable ulcers, or as an alternative to the oral dosage forms for short term use in patients who are unable to take oral medication for the following conditions: hypersensitivity to any component of this product. cross sensitivity in this class of compounds has been observed. therefore, famotidine injection should not be administered to patients with a history of hypersensitivity to other h2 -receptor antagonists.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

mylan institutional llc - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 10 mg in 1 ml - famotidine injection, supplied as a concentrated solution for intravenous injection, is intended for intravenous use only. famotidine injection is indicated in some hospitalized patients with pathological hypersecretory conditions or intractable ulcers, or as an alternative to the oral dosage forms for short term use in patients who are unable to take oral medication for the following conditions: hypersensitivity to any component of these products. cross sensitivity in this class of compounds has been observed. therefore, famotidine injection should not be administered to patients with a history of hypersensitivity to other h2 -receptor antagonists.

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

mckesson corporation - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine is indicated in: 1. short-term treatment of active duodenal ulcer . most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. 3. short-term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. short-term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short- term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies). famotidine is also indicated for the short-term treatment of esophagitis

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

mylan institutional inc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine tablets are indicated in: - short-term treatment of active duodenal ulcer: most adult patients heal within 4 weeks; there is rarely reason to use famotidine tablets at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine tablets in uncomplicated active duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer: controlled studies in adults have not extended beyond one year. - short-term treatment of active benign gastric ulcer: most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine tablets in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. - short-term treatment of gastroesophageal reflux disease (gerd): famotidine tablets are indicated for short-term treatment of patients with symptoms of gerd (see clinical pharmacology in adults: clinical studies). - fa

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

stat rx usa llc - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine tablets are indicated in: 1. short term treatment of active duodenal ulcer . most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. 3. short term treatment of active benign gastric ulcer . most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. short term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies). famotidine is also indicated for the short term treatment of esoph

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

proficient rx lp - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 40 mg - famotidine is indicated in: 1. short-term treatment of active duodenal ulcer. most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. 3. short-term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. short-term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short-term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies ). famotidine is also indicated for the short-term treatment of esopha

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 40 mg - famotidine tablets are indicated in: 1. short term treatment of active duodenal ulcer . most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. 3. short term treatment of active benign gastric ulcer . most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. short term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies). famotidine is also indicated for the short term treatment of esoph

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

carilion materials management - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 40 mg - famotidine tablets are indicated in: 1. . most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. short term treatment of active duodenal ulcer 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. 3. . most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. short term treatment of active benign gastric ulcer 4. famotidine is indicated for short term treatment of patients with symptoms of gerd (see ). short term treatment of gastroesophageal reflux disease (gerd). clin

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

unit dose services - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine is indicated in: 1. short-term treatment of active duodenal ulcer. most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. 3. short-term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. short-term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short-term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies ). famotidine is also indicated for the short-term treatment of esopha